Option chain shows key data for Quoin Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Quoin Pharmaceuticals.

Quoin Pharmaceuticals (NASDAQ:QNRX) Stock, Option Chain

Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

vaccine-4892059

News

QNRX

Shares of Quoin Pharmaceuticals surged 47.5% Wednesday morning. The stock is higher following the release of promising initial data from its ongoing clinical study of QRX003.

Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday

movers image

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATNF

BREA

CLMT

CTCX

EFSH

GEVO

GRTS

KLTO

LCID

MTEM

PRQR

SAIH

STAF

STEC

VINE

VSME

Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

oracle shutter

AMZN

ASNS

CNET

CNTM

EGIO

IONS

NUVB

ORCL

PSIG

RBRK

SGLY

SLXN

SMTK

TVGN

VRDN

WENA

WHLR

Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals Ltd

Health Care

Press Releases

Quoin Pharmaceuticals Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Releases Second Episode of its "Living with Netherton" Series, as part of its ongoing NETHERTON NOW awareness campaign

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Earnings

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

General

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

180 Life Sciences

Azitra

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Ensysce Biosciences

Galecto

Genprex

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mustang Bio

Moleculin Biotech

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

PharmaCyte Biotech

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Synaptogenix

Tharimmune

Xenetic Biosciences

Maxim Group

Alliance Global Partners

Comments

Quoin Pharmaceuticals

Quoin Pharmaceuticals (QNRX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell